Company Profile
Fate Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Fate Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Fate Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Fate Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Fate Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
FATE is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Fate Therapeutics's catalysts are FT819 and the broader iPSC cell-therapy platform, where early data matter a lot. The company still needs human proof that the platform can work.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Source: Fate Therapeutics
- 02
- 03
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Source: Fate Therapeutics
- 04
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Source: Fate Therapeutics
- 05
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Source: Fate Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.